Premium
Synthesis of [ 14 C]boceprevir, [ 13 C 3 ]boceprevir, and [D 9 ]boceprevir, a hepatitis C virus protease inhibitor
Author(s) -
Ren Sumei,
Royster Pernilla,
Lavey Carolee,
Hesk David,
McNamara Paul,
Koharski David,
Truong Van,
Borges Scott
Publication year - 2012
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.1960
Subject(s) - boceprevir , virology , chemistry , hepatitis c virus , protease inhibitor (pharmacology) , protease , ns3 , virus , medicine , biochemistry , ribavirin , enzyme , viral load , antiretroviral therapy
Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor for HCV treatment. [ 14 C]Boceprevir (SCH 503034, trade name Victrelis) was synthesized from K 14 CN in 11 steps with an overall yield of 16.4%. [ 13 C 3 ]Boceprevir was synthesized in 16 steps with a 2.5% overall yield. The carbon‐13 in the molecule was distributed along the peptide chain. [D 9 ]Boceprevir was synthesized from [D 9 ]‐ t ‐butylamine in four steps with an overall yield of 69%. Copyright © 2012 John Wiley & Sons, Ltd.